| Patient | Sarah Walker |
|---|---|
| Date of birth | 1976-12-23 |
| Identifiers | MRN HR-ET019-SYN; SSN (made up) 000-19-7062 |
| Document date | 2026-03-09 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. [S]
Madam Walker returns two weeks after starting losartan 50 mg, empagliflozin 10 mg and atorvastatin 20 mg. She has taken them each morning at home time, including on a four-day trip. Her home readings average 144/90, down from 152/96. The morning headaches have stopped. She has had no dizziness, cough, genital itching or muscle aches, and urinates slightly more in the first hours after the empagliflozin. She had a video session with the dietitian and has made a salt-free version of her seasoning blend. Her hepatitis B, hepatitis C and HIV tests were negative, and she has no hepatitis B immunity. The echocardiogram was done this morning. She leaves next week for three weeks of conventions. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 144/90 on losartan 50 mg |
| Side effects | None |
| Diet | Dietitian session done; salt-free seasoning blend |
| Screening tests | Hepatitis B and C and HIV negative; no hepatitis B immunity |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness or fainting |
| Neurological | Negative | Morning headaches gone |
| Respiratory | Negative | No cough |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 2026-02-23 to 2026-03-09 | completed | S |
| Losartan 100 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-03-09 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 78.2 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 29.4 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 78 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.29 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 51 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
Vital signs recorded on 2026-03-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 148/92, pulse 78; weight 78.2 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Respiratory | Clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 148/92 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 144/90 |
| Examination | Weight and BMI | Every visit | Completed today | 78.2 kg |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Two weeks after starting: potassium 4.6, bicarbonate 24 mmol/L; creatinine 1.29 mg/dL, eGFR 51, a 7% rise; repeat two to four weeks after today's increase |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Up to date | 294 mg/g two weeks ago; next at about three months |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or LVH on ECG | Completed today | Mild concentric LVH; ejection fraction 60% |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | Atorvastatin started two weeks ago; panel at the next visit |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No dizziness, cough, genital itching or muscle aches; doses taken at home time when traveling; sick-day card in her bag |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Dietitian session done; salt-free seasoning; ordering strategies for banquets |
| Laboratory | Hepatitis B, hepatitis C and HIV tests | Once, with the kidney evaluation | Completed today | All negative; no hepatitis B immunity, so vaccination is planned |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)
Follow-up: Potassium and creatinine two to four weeks after the losartan increase. Review in about seven weeks with the urine albumin, kidney function and lipids. Call for dizziness, fainting, or vomiting or diarrhea (hold losartan and empagliflozin). Next scheduled visit 2026-04-27: eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. [S]